单中心连续79例儿童单侧组织学良好型肾母细胞瘤先期手术治疗结果及疗效分析

doi:10.3969/j.issn.1674-8115.2021.10.010

摘要/Abstract

摘要：

目的·加深对先期手术策略治疗儿童肾母细胞瘤（Wilms tumor，WT）的理解，规范手术操作及其后的化学治疗±放射治疗（放疗）流程，为中国儿童WT临床研究提供必要的数据支持。方法·回顾性收集2010年1月1日—2017年12月30日首诊于上海交通大学医学院附属上海儿童医学中心肿瘤外科并获得病理诊断的初治单侧组织学良好型WT（favorable histology Wilms tumor，FHWT）连续病例资料。所有病例均按照中国小儿肿瘤专业委员会（Chinese Children Cancer Group，CCCG）-WT-2009和CCCG-WT-2015方案诊断、分期并接受相应治疗。采用SPSS 25.0软件对手术结果、无事件生存率（event-free survival，EFS）和总体生存率（overall survival，OS）进行分析。最后随访时间为2020年3月31日。结果·共纳入79例初治单侧FHWT连续病例。男性41例，女性38例；中位年龄27.1个月。系统分期Ⅰ期7例，Ⅱ期39例，Ⅲ期23例，Ⅳ期10例。69例（87.3%）一期手术行肾脏肿瘤切除术，10例（12.7%）行肾脏肿瘤活检术（2例粗针穿刺活检，8例开腹活检）。11例患儿出现疾病进展/复发，1例放弃治疗后8周又回到原治疗方案。具有原发灶放疗指征的32例患儿中27例实际接受放疗，10例初诊时有肺转移灶患儿中3例接受全肺放疗。67例无事件病例中位随访时间为69.8个月。所有病例5年EFS和OS分别为84.8%和92.4%；Ⅰ、Ⅱ、Ⅲ以及Ⅳ期患儿5年EFS分别为100.0%、84.6%、95.7%和50.0%（P=0.010），5年OS分别为100.0%、94.9%、95.7%和70.0%（P=0.070）。Ⅲ/Ⅳ期患儿中，一期手术切除原发灶病例5年EFS高于仅实施活检术患儿（91.3% vs 60.0%，P=0.032）；对于先期接受活检术患儿，6周评估可进行根治性手术者较无法根治性手术者5年EFS更高（100% vs 0，P=0.005）。结论·采用先期手术策略治疗儿童单侧FHWT安全、可行且有效。一期手术切除肾原发病灶及准确的淋巴结取样是确定分期和成功治疗的关键。

关键词: 肾母细胞瘤, 组织学良好型, 治疗, 预后, 儿童

Abstract:

Objective·To improve the understanding of upfront surgical strategy in the treatment of Wilms tumor (WT) and standardize the upfront resection procedure and subsequent chemotherapy and/or radiotherapy approach, providing necessary data support for clinical study in childhood WT in China.

Method·From January 1, 2010 to December 30, 2017, the clinical records of patients with unilateral favorable histology WT (FHWT) who were initially diagnosed at Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine were retrospectively collected. All cases were diagnosed, staged and treated according to the Chinese Children Cancer Group (CCCG)-WT-2009 or CCCG-WT-2015 Protocol. Surgical outcome, event-free survival (EFS) and overall survival (OS) were analyzed using SPSS software, version 25.0. Follow-up was updated to March 31, 2020.

Result·A total of 79 consecutive cases with unilateral FHWT were enrolled, including 41 males and 38 females, with a median age of 27.1 months. Systemic staging showed that there were 7 cases with stage Ⅰ, 39 cases with stage Ⅱ, 23 cases with stage Ⅲ and 10 cases with stage Ⅳ. Sixty-nine patients (87.3%) underwent nephrectomy and 10 patients (12.7%) underwent biopsy of renal tumor tissue (2 with core needle biopsy and 8 with open biopsy) in the primary operation. Eleven cases experienced disease progression/recurrence and 1 abandoned treatment and returned to original treatment plan after 8 weeks. Local radiation therapy was applied to 27 of 32 patients with indication. Only 3 of 10 patients with lung metastasis at diagnosis received whole lung radiation therapy. A median follow-up of 69 cases without incident was 69.8 months. The 5-year EFS and OS of all cases were 84.8% and 92.4% respectively. The 5-year EFS of children with stage Ⅰ, Ⅱ, Ⅲ and Ⅳ were 100.0%, 84.6%, 95.7% and 50.0% (P=0.010), respectively. And the 5-year OS of children with stage Ⅰ, Ⅱ, Ⅲ and Ⅳ were 100.0%, 94.9%, 95.7 and 70.0% (P=0.070), respectively. The 5-year EFS of children with stage Ⅲ/Ⅳ receiving initial nephrectomy was higher than that of those undergoing biopsy (91.3% vs 60.0%, P= 0.032). The 5-year EFS of children with initial biopsy, who underwent nephrectomy at week 6 was significantly higher than that of those who did not (100% vs 0, P=0.005).

Conclusion·The upfront tumor surgical strategy of unilateral WT is safe, feasible and effective in the treatment of FHWT. Initial nephrectomy and clearance of all local diseases with lymph nodal sampling is the key to staging and successful treatment.

Key words: Wilms tumor, favorable histology, treatment, prognosis, child

中图分类号:

R726.1

谢晨捷, 高怡瑾, 殷敏智, 蔡骄阳, 张安安, 唐月佳, 顾松, 潘慈, 汤静燕, 徐敏. 单中心连续79例儿童单侧组织学良好型肾母细胞瘤先期手术治疗结果及疗效分析[J]. 上海交通大学学报(医学版), 2021, 41(10): 1330-1335.

Chen-jie XIE, Yi-jin GAO, Min-zhi YIN, Jiao-yang CAI, An-an ZHANG, Yue-jia TANG, Song GU, Ci PAN, Jing-yan TANG, Min XU. Surgical and oncological outcome of 79 consecutive patients with unilateral favorable histology Wilms tumor treated in one single institution following an upfront tumor surgical strategy[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(10): 1330-1335.

图/表 2

参考文献 26

1	汤静燕, 徐敏, 王常林, 等. 小儿肿瘤协会儿童肾母细胞瘤WT-2003协作方案初步报告[J]. 中华小儿外科杂志, 2006, 27(6): 281-284.
2	中国抗癌协会儿科专业委员会, 中华医学会儿科学分会血液学组. 儿童肾肿瘤多中心协作方案诊治随访报告[J]. 中华儿科杂志, 2016, 54(11): 808-813.
3	中国抗癌协会小儿肿瘤专业委员会. 儿童肾母细胞瘤诊断治疗建议(CCCG-WT-2016)[J]. 中华儿科杂志, 2017, 55(2): 90-94.
4	鲍萍萍, 李凯, 吴春晓, 等. 2002—2010年上海市户籍儿童恶性实体肿瘤发病特征和变化趋势分析[J]. 中华儿科杂志, 2013, 51(4): 288-294.
5	Chan CC, To KF, Yuen HL, et al. A 20-year prospective study of Wilms tumor and other kidney tumors: a report from Hong Kong pediatric hematology and oncology study group[J]. J Pediatr Hematol Oncol, 2014, 36(6): 445-450.
6	Mostert S, Arora RS, Arreola M, et al. Abandonment of treatment for childhood cancer: position statement of a SIOP PODC Working Group[J]. Lancet Oncol, 2011, 12(8): 719-720.
7	National Cancer Institute. SEER Cancer Statistics Review(CSR)1975-2018[R/OL]. (2021-04-55)[2021-08-10]. .
8	Smith MA, Altekruse SF, Adamson PC, et al. Declining childhood and adolescent cancer mortality[J]. Cancer, 2014, 120(16): 2497-2506.
9	Dome JS, Graf N, Geller JI, et al. Advances in Wilms tumor treatment and biology: progress through international collaboration[J]. J Clin Oncol, 2015, 33(27): 2999-3007.
10	Yao W, Li K, Xiao X, et al. Outcomes of Wilms' tumor in Eastern China: 10 years of experience at a single center[J]. J Invest Surg, 2012, 25(3): 181-185.
11	Pan C, Cai JY, Xu M, et al. Renal tumor in developing countries: 142 cases from a single institution at Shanghai, China[J]. World J Pediatr, 2015, 11(4): 326-330.
12	黄俊廷, 谭玉婷, 甄子俊, 等. 87例儿童青少年Ⅲ~Ⅳ期预后良好型肾母细胞瘤综合治疗结果分析[J]. 广东医学, 2017, 38(20): 3116-3119.
13	Shamberger RC, Guthrie KA, Richey ML, et al. Surgery-related factors and local recurrence of Wilms tumor in National Wilms Study 4[J]. Ann Surg, 1999, 229(2): 292-297.
14	Aldrink JH, Heaton TE, Dasgupta R, et al. Update on Wilms tumor[J]. J Pediatr Surg, 2019, 54(3): 390-397.
15	Ehrlich PF, Anderson JR, Ritchey ML, et al. Clinicopathologic findings predictive of relapse in children with stage Ⅲ favorable-histology Wilms tumor[J]. J Clin Oncol, 2013, 31(9): 1196-1201.
16	Fernandez CV, Mullen EA, Chi YY, et al. Outcome and prognostic factors in stage Ⅲ favorable-histology Wilms tumor: a report from the children's oncology group study AREN0532[J]. J Clin Oncol, 2018, 36(3): 254-261.
17	Saltzman AF, Smith DE, Gao D, et al. How many lymph nodes are enough? Assessing the adequacy of lymph node yield for staging in favorable histology wilms tumor[J]. J Pediatr Surg, 2019, 54(11): 2331-2335.
18	Nanda RH, Shehata BM, Khoshnam N, et al. Impact of lymph node evaluation in adjuvant and neoadjuvant chemotherapy settings on survival outcomes in Wilms tumour: a review of 185 cases from a single institution[J]. Pathology, 2017, 49(1): 19-23.
19	Ehrlich PF, Ritchey ML, Hamilton TE, et al. Quality assessment for Wilms' tumor: a report from the National Wilms' Tumor Study-5[J]. J Pediatr Surg, 2005, 40(1): 208-212; discussion212-213.
20	Dix DB, Seibel NL, Chi YY, et al. Treatment of stage Ⅳ favorable histology Wilms tumor with lung metastases: a report from the children's oncology group AREN0533 study[J]. J Clin Oncol, 2018, 36(16): 1564-1570.
21	Verschuur A, van Tinteren H, Graf N, et al. Treatment of pulmonary metastases in children with stage Ⅳ nephroblastoma with risk-based use of pulmonary radiotherapy[J]. J Clin Oncol, 2012, 30(28): 3533-3539.
22	Ehrlich PF, Hamilton TE, Grundy P, et al. The value of surgery in directing therapy for patients with Wilms' tumor with pulmonary disease. A report from the National Wilms' Tumor Study Group (National Wilms' Tumor Study 5)[J]. J Pediatr Surg, 2006, 41(1): 162-167.
23	Meisel JA, Guthrie KA, Breslow NE, et al. Significance and management of computed tomography detected pulmonary nodules: a report from the National Wilms Tumor Study Group[J]. Int J Radiat Oncol Biol Phys, 1999, 44 (3): 579-585.
24	常晓峰, 秦红, 杨维, 等. 95例肾母细胞瘤临床病理特点及预后因素分析[J]. 中国肿瘤临床, 2012, 39(15): 1040-1042.
25	Dix DB, Fernandez CV, Chi YY, et al. Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology Wilms tumor: a children's oncology group AREN0532 and AREN0533 study report[J]. J Clin Oncol, 2019, 37(30): 2769-2777.
26	Dome JS, Graf N, Geller JI, et al. Advances in Wilms tumor treatment and biology: progress through international collaboration[J]. J Clin Oncol, 2015, 33(27): 2999-3007.

Item	n （%）
Nephrectomy	69 （87.3）
Transverse incision	64 （92.8）
Subcostal oblique incision	4 （5.8）
Inverted T-shaped incision	1 （1.4）
Tumor rupture	15 （21.7）
Intra-operaton	3 （20.0）
Pre-operation	8 （53.3）
Unknown	4 （26.7）
Biopsy	10 （12.7）
Needle biopsy	2 （20.0）
Open biopsy	8 （80.0）
Complication	4 （5.1）
Intestinal obstruction	2 （50.0）
Chylous leakage	1 （25.0）
Bowel incarcerated in drainage tube incision	1 （25.0）

Item	n （%）
Nephrectomy	69 （87.3）
Transverse incision	64 （92.8）
Subcostal oblique incision	4 （5.8）
Inverted T-shaped incision	1 （1.4）
Tumor rupture	15 （21.7）
Intra-operaton	3 （20.0）
Pre-operation	8 （53.3）
Unknown	4 （26.7）
Biopsy	10 （12.7）
Needle biopsy	2 （20.0）
Open biopsy	8 （80.0）
Complication	4 （5.1）
Intestinal obstruction	2 （50.0）
Chylous leakage	1 （25.0）
Bowel incarcerated in drainage tube incision	1 （25.0）

Item	n / N	5-year EFS / %	P value	5-year OS / %	P value
All cases	12/79	84.8		92.4
Gender			0.215		0.420
Male	4/41	90.2		95.1
Female	8/38	78.9		89.5
Age / month			0.033		0.064
<12	3/16	81.3		100.0
≥12 and <60	4/49	91.8		93.9
≥60 and <120	5/14	64.3		78.6
Stage			0.010		0.070
Ⅰ	0/7	100.0		100.0
Ⅱ	6/39	84.6		94.9
Ⅲ	1/23	95.7		95.7
Ⅳ	5/10	50.0		70.0
Primary Site			1.000		1.000
Right kidney	6/40	85.0		92.5
Left kidney	6/39	84.6		92.3
Pulmonary metastasis	5/10		1.000		1.000
Lung radiation	1^①/3	66.7		66.7
Not lung radiation	4/7	42.9		71.4
FH Ⅰ＋Ⅱ			0.520		1.000
Lymph node biopsy	5/41	87.8		95.1
Not lymph node biopsy	1/5	80.0		100.0
Renal biopsy	4/10		0.005		0.133
Nephrectomy after 6 weeks assessment	0/6	100.0		100.0
Can't receive Nephrectomy after 6 weeks assessment	4/4	0		50.0
FH Ⅲ＋Ⅳ			0.032		0.073
One-stage Nephrectomy	2/23	91.3		95.7
Renal biopsy	4/10	60.0		70.0

Item	n / N	5-year EFS / %	P value	5-year OS / %	P value
All cases	12/79	84.8		92.4
Gender			0.215		0.420
Male	4/41	90.2		95.1
Female	8/38	78.9		89.5
Age / month			0.033		0.064
<12	3/16	81.3		100.0
≥12 and <60	4/49	91.8		93.9
≥60 and <120	5/14	64.3		78.6
Stage			0.010		0.070
Ⅰ	0/7	100.0		100.0
Ⅱ	6/39	84.6		94.9
Ⅲ	1/23	95.7		95.7
Ⅳ	5/10	50.0		70.0
Primary Site			1.000		1.000
Right kidney	6/40	85.0		92.5
Left kidney	6/39	84.6		92.3
Pulmonary metastasis	5/10		1.000		1.000
Lung radiation	1^①/3	66.7		66.7
Not lung radiation	4/7	42.9		71.4
FH Ⅰ＋Ⅱ			0.520		1.000
Lymph node biopsy	5/41	87.8		95.1
Not lymph node biopsy	1/5	80.0		100.0
Renal biopsy	4/10		0.005		0.133
Nephrectomy after 6 weeks assessment	0/6	100.0		100.0
Can't receive Nephrectomy after 6 weeks assessment	4/4	0		50.0
FH Ⅲ＋Ⅳ			0.032		0.073
One-stage Nephrectomy	2/23	91.3		95.7
Renal biopsy	4/10	60.0		70.0

[1]	宣贝贝, 龚赛楠, 刘佳丽, 全权, 孟雨, 牟晓玲. DNA聚合酶θ在子宫内膜癌中的表达及其临床意义[J]. 上海交通大学学报(医学版), 2021, 41(9): 1207-1214.
[2]	李莉莎, 李建辉, 何斌, 吴楠楠, 朱同玉, 郭晓奎, 陈峥宏. 噬菌体治疗泛耐药肺炎克雷伯菌肺部感染的临床应用及效果初探[J]. 上海交通大学学报(医学版), 2021, 41(9): 1272-1276.
[3]	熊雷, 易茜, 许明芳, 陈健. MRPL12在肺腺癌中的表达和预后分析[J]. 上海交通大学学报(医学版), 2021, 41(8): 1033-1040.
[4]	周珺珺, 赵洁, 汤静燕, 蒋马伟, 马秀梅, 白永瑞. Ⅲ~Ⅳ期神经母细胞瘤患儿放射治疗预后因素分析[J]. 上海交通大学学报(医学版), 2021, 41(8): 1051-1055.
[5]	陈盛, 严志龙, 吴晔明, 徐敏, 顾松, 马靖. HIF-1α/SHH信号通路在神经母细胞瘤中的表达及临床意义[J]. 上海交通大学学报(医学版), 2021, 41(8): 1056-1061.
[6]	李静威, 王俐文, 蒋玲曦, 詹茜, 陈皓, 沈柏用. 胰腺癌免疫抑制性肿瘤微环境研究综述[J]. 上海交通大学学报(医学版), 2021, 41(8): 1103-1108.
[7]	凌徐心仪, 张瑶, 钟华. 非小细胞肺癌免疫治疗获益人群筛选的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(8): 1114-1119.
[8]	刘青, 张娜, 邵静波, 李红, 陈凯, 杜成坎, 王真, 蒋慧. MLL基因重排阳性的儿童急性白血病患者的临床特点及预后分析[J]. 上海交通大学学报(医学版), 2021, 41(7): 903-909.
[9]	刘子豪, 唐文芳, 王辉. 儿童脑肿瘤氨基酸PET显像的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(7): 949-952.
[10]	陈博, 赵鹏军. 儿童室性早搏诱发心肌病的危险因素及其干预策略[J]. 上海交通大学学报(医学版), 2021, 41(7): 977-981.
[11]	马韵芳, 潘丽娜, 李圳, 高蓓莉, 胡家安, 徐志红. 司美替尼下调KRAS G12V突变型非小细胞肺癌细胞PD-L1水平的探索性研究[J]. 上海交通大学学报(医学版), 2021, 41(6): 741-748.
[12]	朱嘉莳, 李红, 邵静波, 张娜, 杨静薇, 陈凯, 王真, 蒋慧. 急性淋巴细胞白血病儿童治疗失败原因的分析[J]. 上海交通大学学报(医学版), 2021, 41(6): 764-769.
[13]	程盛, 赵益, 王永琛, 黄平. BRAF基因突变对肝切除后的结直肠癌肝转移患者预后影响的meta分析[J]. 上海交通大学学报(医学版), 2021, 41(6): 786-792.
[14]	陈旭光, 施晟懿, 胡岚, 陈瑜, 陆一鸣, 叶静. 血浆纤维蛋白降解产物对出血性脑卒中患者早期预后的评估价值[J]. 上海交通大学学报(医学版), 2021, 41(5): 612-616.
[15]	胡国芹, 杨程青, 吕钦谕, 赵静, 朱明环, 易正辉, 戴兴海. 计算机化认知矫正治疗对精神分裂症患者认知功能的影响[J]. 上海交通大学学报(医学版), 2021, 41(5): 622-627.